Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has shared an announcement.
China Resources Pharmaceutical Group Ltd. has announced that its board of directors will meet on August 26, 2025, to consider and approve the interim results for the first half of the year and potentially declare an interim dividend. This meeting is significant as it will provide insights into the company’s financial health and could impact shareholder value and market positioning.
The most recent analyst rating on (HK:3320) stock is a Buy with a HK$7.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Ltd. is a company incorporated in Hong Kong, operating within the pharmaceutical industry. It focuses on the production and distribution of pharmaceutical products and services, catering to a diverse market with a significant presence in the industry.
Average Trading Volume: 11,021,089
Technical Sentiment Signal: Sell
Current Market Cap: HK$32.54B
For a thorough assessment of 3320 stock, go to TipRanks’ Stock Analysis page.